These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23651025)

  • 21. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
    Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
    Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunosuppressive agents in pediatric renal transplantation].
    Ismaili K; Abramowicz D; Adams B; Godefroid N; Lolin K; Schurmans T; Hall M; Janssen F
    Rev Med Brux; 2005; 26(6):505-12. PubMed ID: 16454154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
    Ware N; MacPhee IA
    Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A drug safety evaluation of everolimus in kidney transplantation.
    Holdaas H; Midtvedt K; Åsberg A
    Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transplantation between monozygotic twins: how identical are they?
    Day E; Kearns PK; Taylor CJ; Bradley JA
    Transplantation; 2014 Sep; 98(5):485-9. PubMed ID: 25102303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms and kidney transplant outcomes.
    Chand S; McKnight AJ; Borrows R
    Curr Opin Nephrol Hypertens; 2014 Nov; 23(6):605-10. PubMed ID: 25188274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacogenetics of immunosuppressants].
    Cojutti PG; Baraldo M
    G Ital Nefrol; 2015; 32(2):. PubMed ID: 26005938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Cattaneo D; Vinks AA
    Pharmacol Res; 2012 Feb; 65(2):163-7. PubMed ID: 22015636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of long-term impact of immunosuppressants at therapeutic doses on hepatic function and histological changes in unilateral nephrectomized rats.
    Chen Y; Lin H; Zhang Z; Lin Y; Lu Y; Yuan R; Li M; Nie P; Chen L; Qiu J; Chen L; Xu B; Lin W; Xu J; Du H; Liang J; Zhang Z
    Exp Toxicol Pathol; 2014 Dec; 66(9-10):423-8. PubMed ID: 25081300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized treatment in heart transplantation.
    Khush KK
    Curr Opin Organ Transplant; 2017 Jun; 22(3):215-220. PubMed ID: 28266942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics and immunosuppressive drugs.
    Hronová K; Šíma M; Světlík S; Matoušková O; Slanař O
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):821-35. PubMed ID: 25301406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics in solid organ transplantation: a transition from kinetics to dynamics.
    Kuypers DR
    Pharmacogenomics; 2012 Nov; 13(15):1679-83. PubMed ID: 23171332
    [No Abstract]   [Full Text] [Related]  

  • 35. Graft-Derived Cell-Free DNA as a Marker of Transplant Graft Injury.
    Oellerich M; Walson PD; Beck J; Schmitz J; Kollmar O; Schütz E
    Ther Drug Monit; 2016 Apr; 38 Suppl 1():S75-9. PubMed ID: 26418703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variability and transplantation.
    Marder B; Schröppel B; Murphy B
    Curr Opin Urol; 2003 Mar; 13(2):81-9. PubMed ID: 12584466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacogenetics, a valuable aid to therapeutic monitoring of immunosuppressives and antiretrovirals].
    Haufroid V
    Bull Mem Acad R Med Belg; 2011; 166(5-6):191-8; discussion 199-201. PubMed ID: 22891448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers and Pharmacogenomics in Kidney Transplantation.
    Crowley LE; Mekki M; Chand S
    Mol Diagn Ther; 2018 Oct; 22(5):537-550. PubMed ID: 29971647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphisms influencing therapy and susceptibility to rejection in organ allograft recipients.
    Poli F; Piccolo G; Scalamogna M
    BioDrugs; 2002; 16(1):11-7. PubMed ID: 11908998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients.
    Job KM; Roberts JK; Enioutina EY; Illamola SM; Kumar SS; Rashid J; Ward RM; Fukuda T; Sherbotie J; Sherwin CM
    Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):747-765. PubMed ID: 34121566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.